ASCO2017:人类肿瘤异种疫苗可治疗多种癌症

2017-06-06 zhangfan MedSci原创

Bi-vaccine疫苗表现出对多种癌症的治疗能力,有望成为针对所有肿瘤治疗的新武器

研究发现致癌细胞基因组片段进入健康细胞核内时可以诱导细胞自身基因组的变化导致遗传信息的传递改变,若新产生的癌细胞被免疫系统识别则将其摧毁,否则将会导致癌症的发生。基于上述理论,研究人员开发了人异种抗癌疫苗Bi-Vaccine,通过病人的实验室和临床研究进一步证实其预防和治疗能力。

研究人员在体外对淋巴细胞进行改造使其获得识别癌细胞作为外来细胞的能力。Bi-vaccine融合两种疫苗的功能:抗毒素-抗肿瘤疫苗,破坏血液中的毒素和相关的癌细胞;胸腺淋巴细胞疫苗,通过选择性遗传信息破坏恶性肿瘤细胞。

初步研究发现,接种Bi-vaccine的患者可完全治疗癌症并保护所有年龄段的人免受恶性肿瘤的影响。多年来,有数百名各种癌症患者接受了肿瘤疫苗的治疗且不乏晚期癌症患者的成功案例。

研究者认为Bi-vaccine疫苗表现出对多种癌症的治疗能力,有望成为针对所有肿瘤治疗的新武器。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938699, encodeId=f35119386994a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jan 27 04:54:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208164, encodeId=2166208164d7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 08 13:42:57 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207307, encodeId=369b20e30787, content=太好了,加快进度吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Tue Jun 06 11:19:44 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207301, encodeId=436420e30131, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jun 06 11:13:20 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2018-01-27 quxin068
  2. [GetPortalCommentsPageByObjectIdResponse(id=1938699, encodeId=f35119386994a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jan 27 04:54:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208164, encodeId=2166208164d7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 08 13:42:57 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207307, encodeId=369b20e30787, content=太好了,加快进度吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Tue Jun 06 11:19:44 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207301, encodeId=436420e30131, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jun 06 11:13:20 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-08 luominglian113

    学习了,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1938699, encodeId=f35119386994a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jan 27 04:54:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208164, encodeId=2166208164d7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 08 13:42:57 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207307, encodeId=369b20e30787, content=太好了,加快进度吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Tue Jun 06 11:19:44 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207301, encodeId=436420e30131, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jun 06 11:13:20 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-06 1361efd61am

    太好了,加快进度吧。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938699, encodeId=f35119386994a, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sat Jan 27 04:54:00 CST 2018, time=2018-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=208164, encodeId=2166208164d7, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Thu Jun 08 13:42:57 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207307, encodeId=369b20e30787, content=太好了,加快进度吧。, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa562069713, createdName=1361efd61am, createdTime=Tue Jun 06 11:19:44 CST 2017, time=2017-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=207301, encodeId=436420e30131, content=好好的学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jun 06 11:13:20 CST 2017, time=2017-06-06, status=1, ipAttribution=)]
    2017-06-06 忠诚向上

    好好的学习一下

    0

相关资讯

ASCO2017:肿瘤脑转移患者生存期影响因素

肿瘤脑转移病灶数目与患者生存期密切相关,大部分患者不受颅内疾病体积影响,肿瘤突变亚型对脑转移患者的生存期影响不显著

Haematologica:经伊马替尼治疗的慢性粒细胞白血病患者第二个原发恶性肿瘤发病率及相关死亡率如何?

总之,研究人员发现采用伊马替尼治疗的慢性髓细胞白血病患者没有显示出有较高的第二个原发恶性肿瘤的发病率,但是,第二个原发恶性肿瘤的结局比预期更糟糕。

CELL REP:致癌代谢物 2-HG 通过下调 RIP3 促进肿瘤生成

国际知名学术刊物《Cell Reports》在线发表了韩家淮教授课题组和李勤喜课题组的最新合作研究成果“2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter”,揭示了IDH1 R132突变体产生的致癌代谢物2-HG会促进DNMT1与RIP3启动子区域的结合,导致R

ASCO 2017:热点聚焦——新药Larotrectinib(LOXO-101)治疗各种成人及儿童癌症效果卓越

每年的ASCO大会都会有公司一夜爆红。今年,一家名为Loxo的小公司因其核心在研药物larotrectinib(LOXO-101)的早期临床数据成为了ASCO 2017大会上的一匹黑马。larotrectinib是作为一款广谱肿瘤药来开发,拟用于所有表达有原肌球蛋白受体激酶( tropomyosin receptor kinase,TRK)的肿瘤患者,而不是针对某个解剖位置的肿瘤。TRK融合广泛分

STM:靶向抑制两种酶,导致癌症的基因突变得以控制!

德克萨斯大学MD安德森癌症中心的一项研究已经表现出治愈RAS基因突变导致的耐药性癌症的希望。临床前研究结合了靶向针对抑制剂polyADP核糖聚合酶(PARP)和丝裂原活化蛋白激酶(MEK)的治疗。研究结果本周在科学转化医学杂志上发表。

Cancer Res:“饿死”癌细胞的新策略研究获取重要进展!

为了努力使大脑癌细胞挨饿,并对肿瘤发展进行制动,北卡罗莱纳大学治疗综合性癌症中心研究人员阻止了脑肿瘤细胞用于将糖转化为能量的主要途径。他们希望这会使肿瘤细胞饥饿,并减缓其生长。令人吃惊的是,该策略实际上加速了成神经管细胞瘤实验室模型的增长。